Moderate

Opioid use disorder — ED-initiated treatment and harm reduction

OUD treatment · Psychiatry / Behavioural
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

The ED is an opportunity to initiate opioid agonist treatment, provide take-home naloxone and link patients to community services, reducing overdose mortality. Buprenorphine induction (once in objective withdrawal) and harm-reduction measures are increasingly ED-led, coordinated with local substance-misuse services.

Red flags

  • Respiratory depression or reduced GCS (overdose)
  • Signs of injecting-related sepsis (endocarditis, abscess, DVT)
  • Precipitated withdrawal after premature buprenorphine
  • Concurrent benzodiazepine/alcohol use (additive respiratory depression)
  • Pregnancy (specialist management needed)

Assessment

Differential diagnosis

  • Opioid withdrawal (dysphoria, yawning, lacrimation, GI symptoms, dilated pupils)
  • Opioid intoxication/overdose (pinpoint pupils, respiratory depression)
  • Other drug withdrawal (alcohol, benzodiazepine)
  • Sepsis or injection-related infection
  • Coexisting mental illness

Investigations

  • Objective withdrawal score (COWS) before buprenorphine induction
  • Observations, capillary glucose
  • Bloods: FBC, U&E, LFTs, CRP; blood-borne virus screen (offer BBV testing)
  • ECG if methadone considered (QT) or polydrug use
  • Assess injection sites for infection (DVT, abscess, endocarditis)

Management

  • Confirm opioid use disorder and current state (withdrawal vs intoxication)
  • For overdose, resuscitate and give naloxone titrated to restore breathing
  • Offer opioid agonist treatment: induce buprenorphine only once in objective withdrawal (COWS >12) to avoid precipitated withdrawal
  • Coordinate dosing with the patient's community prescriber/key worker (avoid double-dosing with methadone)
  • Provide take-home naloxone and overdose-prevention education
  • Offer blood-borne virus testing and vaccination, and treat injection-related complications
  • Refer to community drug and alcohol services with warm handover
  • Screen for and address mental-health comorbidity

Drugs & doses

Naloxone — 400 mcg IV/IM titrated (lower, e.g. 100 mcg, to avoid acute withdrawal) for overdose; take-home naloxone kit on discharge
Buprenorphine — 4 mg SL initial dose once COWS >12, repeat to 8-16 mg total on day 1 (induction)
Methadone — only continue/prescribe after confirming existing dose with the community prescriber (risk of toxicity)
Lofexidine — 0.8 mg PO for autonomic withdrawal symptoms as an adjunct
Metoclopramide/loperamide — symptomatic relief of nausea/diarrhoea in withdrawal

Disposition

Discharge stabilised patients with take-home naloxone and a warm referral to community drug services, after buprenorphine induction where appropriate; admit for injection-related sepsis or overdose complications, and involve liaison psychiatry for comorbidity.

Complications & pitfalls

  • Overdose death
  • Precipitated withdrawal from early buprenorphine
  • Injection-related infections (endocarditis, abscess, blood-borne viruses)
  • Methadone toxicity/QT prolongation
  • Disengagement from services

Exam pearls

  • Never induce buprenorphine until the patient is in objective withdrawal (COWS >12) — otherwise you precipitate withdrawal
  • Always confirm an existing methadone dose with the prescriber before giving any — unconfirmed dosing can be fatal
  • Take-home naloxone saves lives — supply it and teach its use
  • The ED visit is a key engagement point; warm handover improves uptake
  • Offer blood-borne virus testing and treat injection-site complications

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.